Clinical trials: Neoplasms Recurrence
Waldenstrom Macroglobulinemia, Waldenstrom's Macroglobulinemia Recurrent
A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström Macroglobulinemia
This study will evaluate the safety and efficacy of the BCL2 inhibitor sonrotoclax (BGB-11417) in participants with relapsed/refractory Waldenström's Macroglobulinemia (R/R WM) and in combination with zanubrutinib in adult…
- Conditions
- Waldenstrom Macroglobulinemia, Waldenstrom's Macroglobulinemia Recurrent, Waldenstrom's Macroglobulinemia Refractory
- Trial name
- NCT05952037
- Testing
- Sonrotoclax, Zanubrutinib
- Where
- 72 sites in United States, Australia and 7 more
- Volunteers
- 114 people
- Sponsor
- BeOne Medicines
Hepatocellular Carcinoma
Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.
The primary objective of this study was to evaluate the efficacy of anlotinib hydrochloride capsules combined with penpulimab injection (test group) versus placebo (control group) for adjuvant therapy after radical surgery or…
- Trial name
- NCT05862337
- Testing
- Anlotinib hydrochloride capsules, Penpulimab injection
- Where
- 67 sites in China
- Volunteers
- 480 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Breast Cancer
A Study of Avastin (Bevacizumab) Plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
This single arm study will assess the safety and efficacy of a regimen of Avastin plus a taxane, with or without additional chemotherapy, as first-line treatment in patients with locally recurrent or metastatic breast cancer.
- Trial name
- NCT00448591
- Testing
- bevacizumab [Avastin], Taxane-based chemotherapy
- Where
- 457 sites in Argentina, Australia and 34 more
- Volunteers
- 2,296 people
- Sponsor
- Hoffmann-La Roche
Fallopian Tube Cancer, Metastatic Cancer
SCH-58500 in Treating Patients With Primary Ovarian, Fallopian Tube, or Peritoneal Cancer (C95084)
RATIONALE: Giving the p53 gene for ovarian, fallopian tube, or peritoneal cancer may inhibit tumor growth. Giving the gene directly into the peritoneum may kill more cancer cells.
- Conditions
- Fallopian Tube Cancer, Metastatic Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT00002960
- Testing
- recombinant adenovirus-p53 SCH-58500
- Volunteers
- 59 people
- Sponsor
- Merck Sharp & Dohme LLC
Neoplasms, Endometrial
A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Chinese Participants With Primary Advanced or Recurrent Endometrial Cancer (EC)
The goal of this clinical trial is to see how well dostarlimab works when administered with the chemotherapy drugs carboplatin and paclitaxelin in treating EC in Chinese participants.
- Trial name
- NCT07108270
- Testing
- Dostarlimab, Carboplatin, Paclitaxel
- Where
- China
- Volunteers
- 30 people
- Sponsor
- GlaxoSmithKline
Cervical Cancer
RaPiDS- A Phase 2 Study of Anti-PD-1 Independently or in Combination With Anti-CTLA-4 in Second-Line Cervical Cancer
This is a randomized, blinded, non-comparative, two-arm Phase 2 clinical trial to assess the efficacy and safety of AGEN2034 administered with placebo (Treatment Arm 1 - monotherapy) or with AGEN1884 (Treatment Arm 2- combination…
- Trial name
- NCT03894215
- Testing
- AGEN2034, AGEN1884
- Where
- 68 sites in United States, Brazil and 5 more
- Volunteers
- 211 people
- Sponsor
- Agenus Inc.
Multiple Myeloma in Relapse, Refractory Multiple Myeloma
Combination Study of Pomalidomide, Marizomib, and Low-Dose Dexamethasone in Relapsed and Refractory Multiple Myeloma
This is a Phase 1 clinical trial to evaluate a new combination of drugs for the treatment of relapsed or refractory (drug-resistant) multiple myeloma.
- Conditions
- Multiple Myeloma in Relapse, Refractory Multiple Myeloma, Multiple Myeloma
- Trial name
- NCT02103335
- Testing
- pomalidomide, marizomib, low-dose dexamethasone
- Where
- 6 sites in United States, Australia
- Volunteers
- 38 people
- Sponsor
- Celgene
Mesothelin-Expressing Tumors, Epithelial Ovarian Cancer
CT-95 in Advanced Cancers Associated With Mesothelin Expression
This is a Phase 1a/1b, first-in-human (FIH), open-label, multi-center dose escalation and expansion study of the safety, pharmacokinetics (PK), pharmacodynamics, and antitumor activity of single-agent CT-95 in subjects with…
- Conditions
- Mesothelin-Expressing Tumors, Epithelial Ovarian Cancer, Malignant Pleural Mesothelioma, Advanced, Malignant Peritoneal Mesothelioma, Advanced
- Trial name
- NCT06756035
- Testing
- CT-95
- Where
- 9 sites in United States
- Volunteers
- 70 people
- Sponsor
- Context Therapeutics Inc.
Lymphoma
Phase I, Open-label, Dose Escalation of AZD4877 in Hematologic Malignancies
The primary purpose of this study is to find out what the maximum tolerated dose is for an experimental drug called AZD4877 based on the side effects experienced by patients that receive AZD4877 on a weekly basis in these…
- Trial name
- NCT00460460
- Testing
- AZD4877
- Where
- 3 sites in United States, Canada
- Volunteers
- 75 people
- Sponsor
- AstraZeneca
Nasopharyngeal Neoplasms
Study of Pembrolizumab (MK-3475) in Platinum Pre-treated Recurrent/Metastatic Nasopharyngeal Cancer (MK-3475-122/KEYNOTE-122)
This is a study of pembrolizumab (MK-3475) versus standard treatment (capecitabine, gemcitabine, or docetaxel) for the treatment of recurrent or metastatic nasopharyngeal cancer (NPC).
- Trial name
- NCT02611960
- Testing
- Pembrolizumab, Capecitabine, Gemcitabine
- Volunteers
- 233 people
- Sponsor
- Merck Sharp & Dohme LLC
Hematologic Malignancy
Safety/PK Study of Gene Modified Donor T Cell Infusion in Children With Recurrent Hem Malignancies After Allo Transplant
Phase I, open-label, non-randomized study of safety, pharmacokinetics and efficacy of donor BPX-501 T cell infusion in children with recurrent or minimal residual disease (MRD) hematologic malignancies post-allogeneic transplant.
- Trial name
- NCT03459170
- Testing
- BPX-501 T cells, rimiducid
- Where
- 3 sites in Italy
- Volunteers
- 15 people
- Sponsor
- Bellicum Pharmaceuticals
Prostatic Neoplasms
Phase II Trial of Monoclonal Antibody (J591) in Combination With Low-Dose Subcutaneous Interleukin-2
The monoclonal antibody J591 is being investigated as therapy for patients with prostate cancer, in combination with recombinant interleukin-2 (Proleukin, Aldesleukin).
- Trial name
- NCT00040586
- Testing
- Monoclonal Antibody J591, Recombinant Interleukin-2
- Where
- United States
- Sponsor
- BZL Biologics
Non-Hodgkin Lymphoma
Safety and Efficacy of Entospletinib (ENTO [GS-9973]) Combined With Vincristine (VCR) in Adult Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NHL)
The primary objective of this study is to evaluate the safety of ENTO with VCR in participants with relapsed or refractory B-cell NHL.
- Trial name
- NCT02568683
- Testing
- Entospletinib, Vincristine
- Where
- 7 sites in United States, France
- Volunteers
- 10 people
- Sponsor
- Gilead Sciences
Metastatic Breast Cancer
Anti-tumor Effect of Ixabepilone in Metastatic Breast Cancer (mBC) Selected by the Ixabepilone DRP.
The purpose is to investigate anti-tumor effect of ixabepilone in patients with locally recurrent or metastatic breast cancer (mBC) selected by the Ixabepilone DRP after failure of an anthracycline and taxanes.
- Trial name
- NCT04796324
- Testing
- Ixabepilone Injection
- Where
- 19 sites in Belgium, Finland and 5 more
- Volunteers
- 13 people
- Sponsor
- Allarity Therapeutics
Cutaneous T-cell Lymphoma, Mycosis Fungoides
Pralatrexate and Bexarotene in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma
This study is designed to determine the recommended dose, safety, pharmacokinetics, and early efficacy of the combination of pralatrexate plus oral bexarotene in patients with relapsed or refractory CTCL.
- Conditions
- Cutaneous T-cell Lymphoma, Mycosis Fungoides, Sezary Syndrome, Primary Cutaneous Anaplastic Large Cell Lymphoma
- Trial name
- NCT01134341
- Testing
- Pralatrexate Injection, Bexarotene Capsules, Vitamin B12
- Where
- 5 sites in United States, Italy
- Volunteers
- 34 people
- Sponsor
- Acrotech Biopharma Inc.
Avelumab in Combination With Talazoparib Will be Investigated in Patients With Locally Advanced (Primary or Recurrent) or Metastatic Solid Tumors
Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors
Avelumab in combination with talazoparib will be investigated in patients with locally advanced (primary or recurrent) or metastatic solid tumors, including non-small cell lung cancer (NSCLC), triple negative breast cancer…
- Trial name
- NCT03330405
- Testing
- Avelumab Phase 1b, Talazoparib Phase 1b, Avelumab Phase 2
- Where
- 66 sites in United States, Australia and 7 more
- Volunteers
- 223 people
- Sponsor
- Pfizer
B-cell Acute Lymphoblastic Leukemia
Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
This is a first-in-human, open-label, dose escalation and expansion study of UCART22 administered intravenously to patients with relapsed or refractory B-cell acute Lymphoblastic Leukemia (B-ALL).
- Trial name
- NCT04150497
- Testing
- UCART22, CLLS52
- Where
- 19 sites in United States, France
- Volunteers
- 52 people
- Sponsor
- Cellectis S.A.
Advanced Cancer, Metastatic Cancer
A Open Label Phase I/II Clinical Trial to Evaluate CPI-613 in Patients With Advanced Malignancies
An open label, dose-escalation study to evaluate safety, tolerability, maximum tolerated dose (MTD), efficacy, and pharmacokinetics (PKs) of CPI-613 given twice weekly for three consecutive weeks in cancer patients The objectives…
- Conditions
- Advanced Cancer, Metastatic Cancer, Lymphoma, Solid Tumors
- Trial name
- NCT00741403
- Testing
- CPI-613
- Where
- 4 sites in United States, Canada
- Volunteers
- 39 people
- Sponsor
- Cornerstone Pharmaceuticals
Endometrial Cancer
Hormone Therapy With Arzoxifene Hydrochloride in Treating Women With Recurrent, Advanced, or Metastatic Endometrial Cancer
RATIONALE: Estrogen can stimulate the growth of endometrial cancer cells. Hormone therapy using arzoxifene hydrochloride may fight the endometrial cancer by blocking the use of estrogen by the tumor cells PURPOSE: This phase II…
- Trial name
- NCT00003669
- Testing
- arzoxifene hydrochloride
- Where
- 10 sites in United States
- Sponsor
- Eli Lilly and Company
Anaplastic Thyroid Cancer, Relapsed/Refractory Poorly Differentiated Thyroid Cancer
Study of AIC100 CAR T Cells in Relapsed/Refractory Thyroid Cancer
The purpose of this study is to assess the safety and tolerability and determine the recommended Phase 2 dose of AIC100 Chimeric Antigen Receptor (CAR) T cells in patients with relapsed/refractory poorly differentiated thyroid…
- Trial name
- NCT04420754
- Testing
- AIC100 CAR T Cells
- Where
- 4 sites in United States
- Volunteers
- 70 people
- Sponsor
- AffyImmune Therapeutics, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.